tradingkey.logo

Natera Inc

NTRA
167.350USD
+7.226+4.51%
Cierre 10/03, 16:00ETCotizaciones retrasadas 15 min
22.75BCap. mercado
PérdidaP/E TTM

Más Datos de Natera Inc Compañía

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.

Información de Natera Inc

Símbolo de cotizaciónNTRA
Nombre de la empresaNatera Inc
Fecha de salida a bolsaJul 02, 2015
Director ejecutivoMr. Steven Leonard (Steve) Chapman
Número de empleados4424
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 02
Dirección13011 Mccallen Pass
CiudadAUSTIN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal78753
Teléfono16502499090
Sitio Webhttps://www.natera.com/
Símbolo de cotizaciónNTRA
Fecha de salida a bolsaJul 02, 2015
Director ejecutivoMr. Steven Leonard (Steve) Chapman

Ejecutivos de Natera Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.32M
-1.69%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
311.77K
-0.98%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
152.59K
+0.75%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
88.14K
+1.14%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
43.21K
-6.49%
Mr. Michael Burkes Brophy
Mr. Michael Burkes Brophy
Chief Financial Officer
Chief Financial Officer
8.12K
+86.14%
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Independent Director
6.13K
+1.79%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
3.17K
-28.17%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.32M
-1.69%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
311.77K
-0.98%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
152.59K
+0.75%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
88.14K
+1.14%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%

Desglose de ingresos

Divisa: USDActualizado: jue., 2 de oct
Divisa: USDActualizado: jue., 2 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
537.80M
98.39%
Europe, Middle East, India, Africa
5.41M
0.99%
Asia Pacific and Other
1.82M
0.33%
Americas, excluding U.S
1.57M
0.29%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%

Estadísticas de accionistas

Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.20%
T. Rowe Price Associates, Inc.
8.79%
JP Morgan Asset Management
6.50%
BlackRock Institutional Trust Company, N.A.
4.94%
Farallon Capital Management, L.L.C.
3.51%
Otro
67.06%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.20%
T. Rowe Price Associates, Inc.
8.79%
JP Morgan Asset Management
6.50%
BlackRock Institutional Trust Company, N.A.
4.94%
Farallon Capital Management, L.L.C.
3.51%
Otro
67.06%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
46.29%
Investment Advisor/Hedge Fund
27.68%
Hedge Fund
12.63%
Individual Investor
3.13%
Family Office
2.73%
Family Office
2.73%
Family Office
2.35%
Bank and Trust
1.98%
Research Firm
1.44%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1168
129.04M
94.02%
-3.31M
2025Q2
1137
131.96M
96.64%
-402.16K
2025Q1
1129
133.60M
97.90%
+2.21M
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
2023Q2
792
116.72M
102.40%
-10.10M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
12.62M
9.2%
+279.77K
+2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
12.07M
8.79%
+1.64M
+15.72%
Jun 30, 2025
JP Morgan Asset Management
8.92M
6.5%
+2.53M
+39.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.78M
4.94%
+101.02K
+1.51%
Jun 30, 2025
Farallon Capital Management, L.L.C.
4.82M
3.51%
+274.00K
+6.02%
Jun 30, 2025
State Street Global Advisors (US)
3.32M
2.42%
-53.04K
-1.57%
Jun 30, 2025
Duquesne Family Office LLC
3.09M
2.25%
-317.14K
-9.32%
Jun 30, 2025
Wellington Management Company, LLP
2.63M
1.92%
-426.00K
-13.92%
Jun 30, 2025
RTW Investments L.P.
2.59M
1.89%
+99.00
+0.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.55M
1.86%
+166.77K
+6.99%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: hace 7 horas
Actualizado: hace 7 horas
Nombre
Proporción
Franklin Genomic Advancements ETF
6.39%
Alger Weatherbie Enduring Growth ETF
6.31%
ARK Genomic Revolution ETF
4.63%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.3%
VanEck Biotech ETF
4.26%
Global X Genomics & Biotechnology ETF
4.13%
Alger Mid Cap 40 ETF
3.47%
TrueShares Technology, AI & Deep Learning ETF
3.45%
First Trust NYSE Arca Biotechnology Index Fund
3.4%
WisdomTree BioRevolution Fund
2.63%
Ver más
Franklin Genomic Advancements ETF
Proporción6.39%
Alger Weatherbie Enduring Growth ETF
Proporción6.31%
ARK Genomic Revolution ETF
Proporción4.63%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción4.3%
VanEck Biotech ETF
Proporción4.26%
Global X Genomics & Biotechnology ETF
Proporción4.13%
Alger Mid Cap 40 ETF
Proporción3.47%
TrueShares Technology, AI & Deep Learning ETF
Proporción3.45%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.4%
WisdomTree BioRevolution Fund
Proporción2.63%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI